An integrated bioinformatics approach identifies elevated cyclin e2 expression and e2f activity as distinct features of tamoxifen resistant breast tumors

PLoS ONE

Volumn 6, Issue 7, 2011, Pages

  Huang, Lei ^a   Zhao, Shuangping ^b   Frasor, Jonna M ^b   Dai, Yang ^a  

^a University of Illinois at Chicago   (United States)

^b UNIVERSITY OF ILLINOIS AT CHICAGO   (United States)

Author keywords

[No Author keywords available]

Indexed keywords

2 MORPHOLINO 8 PHENYLCHROMONE; CHRYSIN; CYCLIN E; CYCLIN E2; GALANTAMINE; HARMINE; PHENOTHIAZINE; PROCHLORPERAZINE; RESVERATROL; TAMOXIFEN; THIORIDAZINE; THIORPHAN; TRANSCRIPTION FACTOR E2F; TRICHOSTATIN A; TRIFLUOPERAZINE; TRIMETHYLCOLCHICINIC ACID; UNCLASSIFIED DRUG; CCNE2 PROTEIN, HUMAN; CYCLINE; PHENOTHIAZINE DERIVATIVE;

ARTICLE; BIOINFORMATICS; BREAST CANCER; CANCER CELL CULTURE; CANCER RESISTANCE; CELL CYCLE; CELL PROLIFERATION; CONTROLLED STUDY; DOWN REGULATION; DRUG TARGETING; GENE EXPRESSION PROFILING; GENE FUNCTION; GENE IDENTIFICATION; GENE MAPPING; GENE OVEREXPRESSION; GENETIC CORRELATION; GENETIC DATABASE; HUMAN; HUMAN CELL; MICROARRAY ANALYSIS; SEQUENCE HOMOLOGY; TRANSCRIPTION REGULATION; BIOLOGICAL PHENOMENA AND FUNCTIONS CONCERNING THE ENTIRE ORGANISM; BIOLOGY; BREAST TUMOR; CLASSIFICATION; DNA MICROARRAY; DRUG EFFECT; DRUG RESISTANCE; FEMALE; GENE EXPRESSION REGULATION; GENETICS; METABOLISM; METHODOLOGY; MOLECULAR LIBRARY; TUMOR CELL LINE; TUMOR GENE;

BIOLOGICAL PROCESSES; BREAST NEOPLASMS; CELL LINE, TUMOR; CELL PROLIFERATION; COMPUTATIONAL BIOLOGY; CYCLINS; DATABASES, GENETIC; DRUG RESISTANCE, NEOPLASM; E2F TRANSCRIPTION FACTORS; FEMALE; GENE EXPRESSION PROFILING; GENE EXPRESSION REGULATION, NEOPLASTIC; GENES, NEOPLASM; HUMANS; OLIGONUCLEOTIDE ARRAY SEQUENCE ANALYSIS; PHENOTHIAZINES; PROCHLORPERAZINE; SMALL MOLECULE LIBRARIES; TAMOXIFEN;

EID: 79960338041     PISSN: None     EISSN: 19326203     Source Type: Journal    
DOI: 10.1371/journal.pone.0022274     Document Type: Article

References (44)

1. Jordan VC, Murphy CS, (1990) Endocrine pharmacology of antiestrogens as antitumor agents. Endocr Rev 11: 578-610.
2. Katzenellenbogen BS, Miller MA, Mullick A, Sheen YY, (1985) Antiestrogen action in breast cancer cells: modulation of proliferation and protein synthesis, and interaction with estrogen receptors and additional antiestrogen binding sites. Breast Cancer Res Treat 5: 231-243.
3. Arpino G, De Angelis C, Giuliano M, Giordano A, Falato C, et al. (2009) Molecular Mechanism and Clinical Implications of Endocrine Therapy Resistance in Breast Cancer. Oncology 77: 23.
4. Loi S, Haibe-Kains B, Desmedt C, Lallemand F, Tutt AM, et al. (2007) Definition of Clinically Distinct Molecular Subtypes in Estrogen Receptor-Positive Breast Carcinomas Through Genomic Grade. J Clin Oncol 25: 1239-1246.
5. Loi S, Haibe-Kains B, Desmedt C, Wirapati P, Lallemand F, et al. (2008) Predicting prognosis using molecular profiling in estrogen receptor-positive breast cancer treated with tamoxifen. BMC Genomics 9: 239.
6. Loi S, Piccart M, Sotiriou C, (2007) The use of gene-expression profiling to better understand the clinical heterogeneity of estrogen receptor positive breast cancers and tamoxifen response. Crit Rev Oncol Hematol 61: 187-194.
7. Chanrion M, Negre V, Fontaine H, Salvetat N, Bibeau F, et al. (2008) A Gene Expression Signature that Can Predict the Recurrence of Tamoxifen-Treated Primary Breast Cancer. Clinical Cancer Research 14: 1744-1752.
8. Jansen MPHM, Foekens JA, van Staveren IL, Dirkzwager-Kiel MM, Ritstier K, et al. (2005) Molecular Classification of Tamoxifen-Resistant Breast Carcinomas by Gene Expression Profiling. J Clin Oncol 23: 732-740.
9. Barrett T, Troup DB, Wilhite SE, Ledoux P, Rudnev D, et al. (2009) NCBI GEO: archive for high-throughput functional genomic data. Nucleic Acids Res 37: D885-890.
10. Adjuvant! Online. Available: http://www.adjuvantonline.com. Accessed 2011 Jun 23.
11. Group EBCTC (1998) Tamoxifen for early breast cancer: an overview of the randomised trials. Early Breast Cancer Trialists' Collaborative Group. Lancet 351: 1451-1467.
12. Gentleman RC, Carey VJ, Bates DM, Bolstad B, Dettling M, et al. (2004) Bioconductor: open software development for computational biology and bioinformatics. Genome Biology 5: R80.
13. Bolstad BM, Irizarry RA, Astrand M, Speed TP, (2003) A comparison of normalization methods for high density oligonucleotide array data based on variance and bias. Bioinformatics 19: 185-193.
14. Dai M, Wang P, Boyd AD, Kostov G, Athey B, et al. (2005) Evolving gene/transcript definitions significantly alter the interpretation of GeneChip data. Nucl Acids Res 33: e175-.
15. Smyth GK, (2004) Linear models and empirical bayes methods for assessing differential expression in microarray experiments. Stat Appl Genet Mol Biol 3: Article3.
16. Huang DW, Sherman BT, Lempicki RA, (2008) Systematic and integrative analysis of large gene lists using DAVID bioinformatics resources. Nat Protocols 4: 44.
17. Subramanian A, Tamayo P, Mootha VK, Mukherjee S, Ebert BL, et al. (2005) Gene set enrichment analysis: a knowledge-based approach for interpreting genome-wide expression profiles. Proc Natl Acad Sci U S A 102: 15545-15550.
18. TRANSFAC. Available: http://www.gene-regulation.com. Accessed 2011 Jun 23.
19. MSigDB. Availabe: http://www.broadinstitute.org/gsea/msigdb/index.jsp. Accessed 2011 Jun 23.
20. Ben-Porath I, Thomson MW, Carey VJ, Ge R, Bell GW, et al. (2008) An embryonic stem cell-like gene expression signature in poorly differentiated aggressive human tumors. Nat Genet 40: 499-507.
21. Connectivity Map. Available: http://www.broadinstitute.org/cmap. Accessed 2011 Jun 23.
22. Lamb J, Crawford ED, Peck D, Modell JW, Blat IC, et al. (2006) The Connectivity Map: using gene-expression signatures to connect small molecules, genes, and disease. Science 313: 1929-1935.
23. Frasor J, Weaver A, Pradhan M, Dai Y, Miller LD, et al. (2009) Positive Cross-Talk between Estrogen Receptor and NF-kappa B in Breast Cancer. Cancer Research 69: 8918-8925.
24. Stanculescu A, Bembinster LA, Borgen K, Bergamaschi A, Wiley E, et al. (2010) Estrogen Promotes Breast Cancer Cell Survival in an Inhibitor of Apoptosis (IAP)-Dependent Manner. Horm Cancer 1: 127-135.
25. Felice DL, Sun J, Liu RH, (2009) A modified methylene blue assay for accurate cell counting. Journal of Functional Foods 1: 109-118.
26. Wu CL, Zukerberg LR, Ngwu C, Harlow E, Lees JA, (1995) In vivo association of E2F and DP family proteins. Mol Cell Biol 15: 2536-2546.
27. Lamb J, (2007) The Connectivity Map: a new tool for biomedical research. Nat Rev Cancer 7: 54-60.
28. Arpino G, Gutierrez C, Weiss H, Rimawi M, Massarweh S, et al. (2007) Treatment of human epidermal growth factor receptor 2-overexpressing breast cancer xenografts with multiagent HER-targeted therapy. J Natl Cancer Inst 99: 694-705.
29. van Slooten HJ, Bonsing BA, Hiller AJ, Colbern GT, van Dierendonck JH, et al. (1995) Outgrowth of BT-474 human breast cancer cells in immune-deficient mice: a new in vivo model for hormone-dependent breast cancer. Br J Cancer 72: 22-30.
30. Musgrove EA, Sutherland RL, (2009) Biological determinants of endocrine resistance in breast cancer. Nat Rev Cancer 9: 631-643.
31. Vendrell JA, Ghayad S, Ben-Larbi S, Dumontet C, Mechti N, et al. (2007) A20/TNFAIP3, a new estrogen-regulated gene that confers tamoxifen resistance in breast cancer cells. Oncogene 26: 4656-4667.
32. Payton M, Scully S, Chung G, Coats S, (2002) Deregulation of cyclin E2 expression and associated kinase activity in primary breast tumors. Oncogene 21: 8529-8534.
33. Desmedt C, Ouriaghli FE, Durbecq V, Soree A, Colozza MA, et al. (2006) Impact of cyclins E, neutrophil elastase and proteinase 3 expression levels on clinical outcome in primary breast cancer patients. Int J Cancer 119: 2539-2545.
34. Musgrove EA, Sergio CM, Loi S, Inman CK, Anderson LR, et al. (2008) Identification of Functional Networks of Estrogen- and c-Myc-Responsive Genes and Their Relationship to Response to Tamoxifen Therapy in Breast Cancer. PLoS ONE 3: e2987.
35. Sorlie T, Perou CM, Tibshirani R, Aas T, Geisler S, et al. (2001) Gene expression patterns of breast carcinomas distinguish tumor subclasses with clinical implications. Proc Natl Acad Sci U S A 98: 10869-10874.
36. Loi S, Sotiriou C, Haibe-Kains B, Lallemand F, Conus NM, et al. (2009) Gene expression profiling identifies activated growth factor signaling in poor prognosis (Luminal-B) estrogen receptor positive breast cancer. BMC Med Genomics 2: 37.
37. Li Z, Joyal JL, Sacks DB, (2001) Calmodulin enhances the stability of the estrogen receptor. J Biol Chem 276: 17354-17360.
38. Tari AM, Simeone AM, Li YJ, Gutierrez-Puente Y, Lai S, et al. (2005) Cyclooxygenase-2 protein reduces tamoxifen and N-(4-hydroxyphenyl)retinamide inhibitory effects in breast cancer cells. Lab Invest 85: 1357-1367.
39. Gulino A, Barrera G, Vacca A, Farina A, Ferretti C, et al. (1986) Calmodulin antagonism and growth-inhibiting activity of triphenylethylene antiestrogens in MCF-7 human breast cancer cells. Cancer Res 46: 6274-6278.
40. Frankfurt OS, Sugarbaker EV, Robb JA, Villa L, (1995) Synergistic induction of apoptosis in breast cancer cells by tamoxifen and calmodulin inhibitors. Cancer Lett 97: 149-154.
41. Yde CW, Clausen MP, Bennetzen MV, Lykkesfeldt AE, Mouritsen OG, et al. (2009) The antipsychotic drug chlorpromazine enhances the cytotoxic effect of tamoxifen in tamoxifen-sensitive and tamoxifen-resistant human breast cancer cells. Anticancer Drugs 20: 723-735.
42. Murren JR, Durivage HJ, Buzaid AC, Reiss M, Flynn SD, et al. (1996) Trifluoperazine as a modulator of multidrug resistance in refractory breast cancer. Cancer Chemother Pharmacol 38: 65-70.
43. Tafani M, Schito L, Anwar T, Indelicato M, Sale P, et al. (2008) Induction of autophagic cell death by a novel molecule is increased by hypoxia. Autophagy 4: 1042-1053.
44. Zhang L, Yu J, Pan H, Hu P, Hao Y, et al. (2007) Small molecule regulators of autophagy identified by an image-based high-throughput screen. Proc Natl Acad Sci U S A 104: 19023-19028.